Ajanta Pharma Limited Stock

Equities

AJANTPHARM

INE031B01049

Pharmaceuticals

Delayed NSE India S.E. 07:43:51 2024-06-10 am EDT 5-day change 1st Jan Change
2,415 INR -0.24% Intraday chart for Ajanta Pharma Limited +3.79% +15.89%
Sales 2024 42.09B 504M Sales 2025 * 47.29B 566M Capitalization 305B 3.65B
Net income 2024 8.16B 97.74M Net income 2025 * 9.46B 113M EV / Sales 2024 6.67 x
Net cash position 2024 * 7.97B 95.45M Net cash position 2025 * 8.39B 100M EV / Sales 2025 * 6.27 x
P/E ratio 2024
34.4 x
P/E ratio 2025 *
32.4 x
Employees 7,713
Yield 2024 *
0.84%
Yield 2025 *
0.74%
Free-Float 33.58%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.02%
1 week+4.03%
Current month+3.73%
1 month+1.80%
3 months+15.14%
6 months+28.26%
Current year+16.15%
More quotes
1 week
2 111.05
Extreme 2111.05
2 495.00
1 month
2 111.05
Extreme 2111.05
2 495.00
Current year
1 998.35
Extreme 1998.35
2 540.00
1 year
1 380.00
Extreme 1380
2 540.00
3 years
1 061.77
Extreme 1061.7667
2 540.00
5 years
550.00
Extreme 550
2 540.00
10 years
321.35
Extreme 321.3467
2 540.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 98-12-31
Chief Executive Officer 52 95-12-31
Director of Finance/CFO 59 98-04-22
Members of the board TitleAgeSince
Chief Executive Officer 52 95-12-31
Chairman 77 79-12-30
Director/Board Member 78 08-10-19
More insiders
Date Price Change Volume
24-06-10 2,415 -0.24% 68 970
24-06-07 2,421 +5.17% 154,569
24-06-06 2,302 -1.06% 46,104
24-06-05 2,326 +1.54% 106,420
24-06-04 2,291 -1.53% 151,120

Delayed Quote NSE India S.E., June 10, 2024 at 05:32 am EDT

More quotes
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2,421 INR
Average target price
2,440 INR
Spread / Average Target
+0.80%
Consensus
  1. Stock Market
  2. Equities
  3. AJANTPHARM Stock